Risa Wakiya1, Kiyo Ueeda2, Hiromi Shimada2, Shusaku Nakashima2, Tomohiro Kameda2, Nobuyuki Miyatake3, Mikiya Kato2, Taichi Miyagi2, Koichi Sugihara2, Mao Mizusaki2, Rina Mino2, Norimitsu Kadowaki2, Hiroaki Dobashi2. 1. Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa University, 1750-1 Ikenobe, Miki-cho, Kita-gun, Kagawa, 761-0793, Japan. wakiya.risa@kagawa-u.ac.jp. 2. Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa University, 1750-1 Ikenobe, Miki-cho, Kita-gun, Kagawa, 761-0793, Japan. 3. Department of Hygiene, Faculty of Medicine, Kagawa University, Kagawa, Japan.
Abstract
BACKGROUND: In patients with systemic lupus erythematosus (SLE), a higher frequency of atherosclerotic lesions is associated with poor prognosis. Hydroxychloroquine (HCQ) has been reported to improve the lifespan and the prognosis of dyslipidaemia in patients with SLE, but the mechanism is unclear. We investigated the effect of supplemental HCQ treatment on the levels of serum cytokines associated with atherosclerosis in patients with stable SLE. METHODS: Patients with SLE who received supplemental HCQ and maintained low disease activity between January 2016 and September 2020 were included in this study. Disease activity was assessed using Safety of Estrogens in Lupus National Assessment-SLE Disease Activity Index, Cutaneous Lupus Erythematous Disease Area and Severity Index, and Lupus Low Disease Activity State. Serum complement titres, anti-dsDNA antibodies, and serum cytokines (adiponectin, resistin, and leptin) were analyzed before and after HCQ treatment. RESULTS: Forty-one patients (4 males and 37 females, mean age 41.3 ± 13.2 years) were included. Serum adiponectin levels were significantly increased after 3 months of HCQ treatment compared to baseline, and serum resistin levels were significantly reduced. The change in serum resistin level after HCQ administration was correlated with a significant reduction in serum TNF-α, interleukin (IL)-6, IL-8, and IL-1RA levels. CONCLUSIONS: Supplemental HCQ treatment in patients with SLE improved adipokine levels. HCQ may improve prognosis by controlling disease activity in SLE and reducing risk factors for atherosclerosis. Key Points • Hydroxychloroquine has been reported to improve the prognosis of dyslipidaemia in patients with SLE, but the underlying mechanism is unclear. • In this study, hydroxychloroquine improved adipokine levels in patients with SLE, implicating adipokines as a potential mechanism underlying the benefit of hydroxychloroquine on dyslipidaemia. • Supplemental hydroxychloroquine should be considered in patients with SLE harboring lipid abnormalities and risk factors for atherosclerosis.
BACKGROUND: In patients with systemic lupus erythematosus (SLE), a higher frequency of atherosclerotic lesions is associated with poor prognosis. Hydroxychloroquine (HCQ) has been reported to improve the lifespan and the prognosis of dyslipidaemia in patients with SLE, but the mechanism is unclear. We investigated the effect of supplemental HCQ treatment on the levels of serum cytokines associated with atherosclerosis in patients with stable SLE. METHODS: Patients with SLE who received supplemental HCQ and maintained low disease activity between January 2016 and September 2020 were included in this study. Disease activity was assessed using Safety of Estrogens in Lupus National Assessment-SLE Disease Activity Index, Cutaneous Lupus Erythematous Disease Area and Severity Index, and Lupus Low Disease Activity State. Serum complement titres, anti-dsDNA antibodies, and serum cytokines (adiponectin, resistin, and leptin) were analyzed before and after HCQ treatment. RESULTS: Forty-one patients (4 males and 37 females, mean age 41.3 ± 13.2 years) were included. Serum adiponectin levels were significantly increased after 3 months of HCQ treatment compared to baseline, and serum resistin levels were significantly reduced. The change in serum resistin level after HCQ administration was correlated with a significant reduction in serum TNF-α, interleukin (IL)-6, IL-8, and IL-1RA levels. CONCLUSIONS: Supplemental HCQ treatment in patients with SLE improved adipokine levels. HCQ may improve prognosis by controlling disease activity in SLE and reducing risk factors for atherosclerosis. Key Points • Hydroxychloroquine has been reported to improve the prognosis of dyslipidaemia in patients with SLE, but the underlying mechanism is unclear. • In this study, hydroxychloroquine improved adipokine levels in patients with SLE, implicating adipokines as a potential mechanism underlying the benefit of hydroxychloroquine on dyslipidaemia. • Supplemental hydroxychloroquine should be considered in patients with SLE harboring lipid abnormalities and risk factors for atherosclerosis.
Authors: George Bertsias; Dimitrios T Boumpas; Antonis Fanouriakis; Myrto Kostopoulou; Alessia Alunno; Martin Aringer; Ingeborg Bajema; John N Boletis; Ricard Cervera; Andrea Doria; Caroline Gordon; Marcello Govoni; Frédéric Houssiau; David Jayne; Marios Kouloumas; Annegret Kuhn; Janni L Larsen; Kirsten Lerstrøm; Gabriella Moroni; Marta Mosca; Matthias Schneider; Josef S Smolen; Elisabet Svenungsson; Vladimir Tesar; Angela Tincani; Anne Troldborg; Ronald van Vollenhoven; Jörg Wenzel Journal: Ann Rheum Dis Date: 2019-03-29 Impact factor: 19.103
Authors: Gregory Katz; Nathaniel R Smilowitz; Ashira Blazer; Robert Clancy; Jill P Buyon; Jeffrey S Berger Journal: Mayo Clin Proc Date: 2019-07-11 Impact factor: 7.616
Authors: Mary Chester M Wasko; Candace K McClure; Sheryl F Kelsey; Kimberly Huber; Trevor Orchard; Frederico G S Toledo Journal: Diabetologia Date: 2015-07-22 Impact factor: 10.122
Authors: M Mosca; C Tani; M Aringer; S Bombardieri; D Boumpas; R Brey; R Cervera; A Doria; D Jayne; M A Khamashta; A Kuhn; C Gordon; M Petri; O P Rekvig; M Schneider; Y Sherer; Y Shoenfeld; J S Smolen; R Talarico; A Tincani; R F van Vollenhoven; M M Ward; V P Werth; L Carmona Journal: Ann Rheum Dis Date: 2009-11-05 Impact factor: 19.103
Authors: Claire Rempenault; Bernard Combe; Thomas Barnetche; Cécile Gaujoux-Viala; Cédric Lukas; Jacques Morel; Charlotte Hua Journal: Ann Rheum Dis Date: 2017-09-25 Impact factor: 19.103
Authors: Laura Durcan; Deborah A Winegar; Margery A Connelly; James D Otvos; Laurence S Magder; Michelle Petri Journal: J Rheumatol Date: 2016-02-01 Impact factor: 4.666
Authors: Frederico G S Toledo; Rachel G Miller; Nicole L Helbling; Yingze Zhang; James P DeLany Journal: Diabetes Obes Metab Date: 2021-02-21 Impact factor: 6.408